Clinical and Experimental Immunology
I N T E R L A K E N L E A D E R S H I P AWA R D S
7th International Immunoglobulin Conference: Interlaken Leadership Awards
M. C. Dalakas*† and W. N. Löscher‡ *University of Athens Medical School, Athens, Greece , †Thomas Jefferson University, Philadelphia, PA, USA, and ‡Innsbruck Medical University, Innsbruck, Austria
Correspondence: M.C. Dalakas. E-mail: [email protected]
Summary The research presented in this section explores novel applications of immunoglobulin (Ig) therapy in neurological disorders. The results from the upcoming and ongoing trials of Drs Honnorat and Gamez are expected to provide meaningful insights into the treatment of two serious and disabling diseases. The results already being reported from the work of Drs Schmidt and Geis in animal models seem promising, but further proof-of-concept research is warranted to translate their significance to human diseases. Dr Goebel’s work in developing animal models of complex regional pain syndrome (CRPS) may provide new insights into predicting which CRPS patients could respond to Ig therapy or other immunotherapies. The work being made possible by a number of the Interlaken Leadership Awards may provide fundamental insights in understanding neurological disorders and improving quality of life for the patients who suffer from them.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 178: 138
This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.